((4AS,8AS)-4-(4-AMINO-6,7-DIMETHOXYQUINAZOLIN-2-YL)OCTAHYDROQUINOXALIN-1(2H)-YL)(5-METHOXYFURAN-2-YL)METHANONE HYDROCHLORIDE


Molecule Category	Salt-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	JYZGMCKAPNYCEI-QJHJCNPRSA-N
Smiles	Cl.COc1oc(cc1)C(=O)N2CCN([C@H]3CCCC[C@H]23)c4nc(N)c5cc(OC)c(OC)cc5n4
InChI	InChI=1S/C24H29N5O5.ClH/c1-31-19-12-14-15(13-20(19)32-2)26-24(27-22(14)25)29-11-10-28(16-6-4-5-7-17(16)29)23(30)18-8-9-21(33-3)34-18;/h8-9,12-13,16-17H,4-7,10-11H2,1-3H3,(H2,25,26,27);1H/t16-,17-;/m0./s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C24H30ClN5O5
Molecular Weight	503.98
AlogP	3.65
Hydrogen Bond Acceptor	8.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	5.0
Polar Surface Area	116.18
Molecular species	BASE
Aromatic Rings	3.0
Heavy Atoms	34.0

Assay Description	Organism	Bioactivity
Selectivity ratio for antagonist activity at alpha1D adrenergic receptor in Rattus norvegicus (rat) aorta to antagonist activity at alpha1A adrenergic receptor in vas deferens	Rattus norvegicus	1.6
Selectivity ratio for antagonist activity at alpha1B adrenergic receptor in Rattus norvegicus (rat) spleen to antagonist activity at alpha1D adrenergic receptor in aorta	Rattus norvegicus	457.0
Selectivity ratio for antagonist activity at alpha1B adrenergic receptor in Rattus norvegicus (rat) spleen to antagonist activity at alpha1A adrenergic receptor in rat vas deferens	Rattus norvegicus	724.0
Competitive antagonist activity at alpha1D adrenergic receptor in Rattus norvegicus (rat) aorta assessed as inhibition of (-)-noradrenaline-induced contraction	Rattus norvegicus	89.13 nM
Noncompetitive antagonist activity at alpha1B adrenergic receptor in Rattus norvegicus (rat) spleen assessed as inhibition of (-)-phenylephrine-induced contraction	Rattus norvegicus	9.71
Competitive antagonist activity at alpha1A adrenergic receptor in Rattus norvegicus (rat) vas deferens assessed as inhibition of (-)-noradrenaline-induced contraction	Rattus norvegicus	141.25 nM
Selectivity ratio of Ki for Homo sapiens (human) alpha1D adrenergic receptor to Ki for Homo sapiens (human) alpha1A adrenergic receptor	Homo sapiens	8.0
Selectivity ratio of Ki for Homo sapiens (human) alpha1B adrenergic receptor to Ki for Homo sapiens (human) alpha1D adrenergic receptor	Homo sapiens	4.0
Selectivity ratio of Ki for Homo sapiens (human) alpha1B adrenergic receptor to Ki for Homo sapiens (human) alpha1A adrenergic receptor	Homo sapiens	32.0
Displacement of [3H]prazosin from Homo sapiens (human) alpha1D adrenergic receptor	Homo sapiens	3.63 nM
Displacement of [3H]prazosin from Homo sapiens (human) alpha1B adrenergic receptor	Homo sapiens	0.871 nM
Displacement of [3H]prazosin from Homo sapiens (human) alpha1A adrenergic receptor	Homo sapiens	27.54 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL2261607
PubChem	76308473

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).